BiotechTube

rabeprazole + rabeprazole

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastroesophageal Reflux Disease (GERD)

Conditions

Gastroesophageal Reflux Disease (GERD)

Trial Timeline

Jan 1, 2009 → Jan 1, 2011

NCT ID
NCT00787891

About rabeprazole + rabeprazole

rabeprazole + rabeprazole is a phase 3 stage product being developed by Eisai for Gastroesophageal Reflux Disease (GERD). The current trial status is completed. This product is registered under clinical trial identifier NCT00787891. Target conditions include Gastroesophageal Reflux Disease (GERD).

What happened to similar drugs?

18 of 20 similar drugs in Gastroesophageal Reflux Disease (GERD) were approved

Approved (18) Terminated (2) Active (2)
✅rabeprazole and pantoprazoleEisaiApproved
✅rabeprazole + pantoprazoleEisaiApproved
✅Placebo + CisaprideJohnson & JohnsonApproved
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅EsomeprazoleAstraZenecaApproved
✅EsomeprazoleAstraZenecaApproved
✅Esomeprazole 40mg + Pantoprazole 40mg + Lansoprazole 30mgAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01398410Phase 2/3Completed
NCT00787891Phase 3Completed

Competing Products

20 competing products in Gastroesophageal Reflux Disease (GERD)

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXdDaiichi SankyoPhase 1/2
39
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
35
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
FamotidineAstellas PharmaPhase 2/3
38
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
28
E3810 + E3810 + PlaceboEisaiPhase 3
40
Rabeprazole ER + RanitidineEisaiPhase 3
40
E3710 + E3710EisaiPhase 1
29
rabeprazole and pantoprazoleEisaiApproved
43
Rabeprazole 20 mgEisaiPhase 2
35
rabeprazole sodiumEisaiPhase 2
35
RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUMEisaiPhase 3
40
Rabeprazole sodium + EsomeprazoleEisaiPhase 3
40
rabeprazole sodium + PlaceboEisaiPhase 3
40